Full Text View
Tabular View
No Study Results Posted
Related Studies
Peginterferon Alfa-2a and Ribavirin for Genotype 2 Chronic Hepatitis C: Duration and Ribavirin Dose Stratified by RVR
This study is currently recruiting participants.
Verified March 2013 by National Taiwan University Hospital
Study NCT00532701   Information provided by National Taiwan University Hospital

First Received on September 18, 2007.   Last Updated on March 5, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Chronic Hepatitis C
Additional conditions recognized in this trial
Hepatitis
Hepatitis A
Hepatitis C
Hepatitis C, Chronic
Hepatitis, Chronic
More general conditions related to this trial
Digestive System Diseases
Enterovirus Infections
Flaviviridae Infections
Hepatitis, Viral, Human
Liver Diseases
Picornaviridae Infections
RNA Virus Infections
Virus Diseases
Additional drug interventions recognized in this trial
Interferon Alfa-2a
Interferon-alpha
Interferons
Peginterferon alfa-2a
Ribavirin
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Infective Agents
Antimetabolites
Antineoplastic Agents
Antiviral Agents
Growth Inhibitors
Growth Substances
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
National Taiwan University Hospital
National Science Council, Taiwan
Department of Health, Executive Yuan, R.O.C. (Taiwan)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services